How Does Cold Plasma Enhance Seed Germination and Plant Growth?

When we think about the greatest threat facing humanity, we tend to picture climate change and antibiotic resistance, not what we are going to have for dinner. But the truth is, our need for food poses one of the biggest challenges to the planet. According to an estimate by the Food and Agricultural Organization of the United Nations (FAO), by 2050 the world’s population will reach 9.1 billion – almost all of this increase will occur in developing countries (1). To feed that many people, world food production will need to increase vastly, and food production in the developing world will need to double. By 2050 we will need to feed two billion more people. Is there a way to do that?

Spotlight

Aspetar

Aspetar is the first specialised Orthopaedic and Sports Medicine Hospital in the Gulf region. It provides the highest possible medical treatment for sports-related injuries in a state-of-the-art facility, staffed by some of the world’s leading sports medicine practitioners and researchers. Through the delivery of excellence in sports medicine, physiotherapy, sports science, orthopaedic surgery and rehabilitation, Aspetar services the needs of football and Sports Clubs and Federations throughout the state of Qatar, and regularly services international athletes and professional sportspeople.

OTHER ARTICLES
MedTech

How to Choose a Reliable Biotech Clinical Trial Management System?

Article | July 11, 2022

Introduction The medical and life-science industries are experiencing a robust transformation with the increasing prevalence of various types of diseases, including infectious diseases, chronic disorders, and acute conditions around the world. As a result, a significant rise in demand for more effective therapeutic drugs and bionics is being witnessed, leading to a swift increase in the number of clinical trials. For a successful trial, it is important for biotech companies to ensure the data submitted to regulatory bodies regarding clinical trials is accurate, reliable, and definitive from an ethical point of view. A reliable clinical trial management system plays a vital role in collecting, monitoring, and managing clinical data. The availability of high-quality clinical data also helps clinical research institutions make efficient treatment decisions and provide proper patient care. Hence, a number of biotech companies and research organizations are focusing on leveraging innovative clinical trial management solutions to handle a large amount of data, particularly in multi-center trials, and generate reliable, high-quality, and statistically sound data from clinical trials. However, selecting the most appropriate and reliable clinical trial management system is vital for the clinical trial's success. Let's see some of the steps that will assist these firms in choosing the right CTMS. Key Steps for Selecting Right Biotech Clinical Trial Management System Prioritize Study Needs Considering and prioritizing study needs is a crucial step in choosing the most reliable clinical trial management system for biotech companies. Prioritizing helps them to identify a solution that improves the study's quality and removes uncertainty for researchers when faced with difficult choices. Hence, biotech and life-science organizations should choose a clinical trial system that is simple to use, well-organized, and suitably designed to minimize the number of clicks required to complete a task. Select CTMS with Multiple Integrations Integrated clinical trial management systems provide the best value for the companies’ funds as they guarantee the smooth functioning of research protocols. In addition, integrations are necessary to fully understand the importance and advantages of clinical trial management software for ensuring smooth transitions between site management and data collection. Biotech and clinical research should look for CTMS platforms that can integrate with electronic medical record (EMR) platforms and clinical research process content (CRPC) billing grids. This will allow them to use the same billing designations and ensure compliance while minimizing the need for duplicate processes. Ensure System Compliance and Security Clinical research organizations need to adhere to a plethora of complex regulations in order to ensure compliance with one of the most challenging environments of principles, which is information security and privacy. Security and system compliance are vital aspects of choosing the right CTMS solutions for biotech firms as they assist in building trust and form a part of the system’s duties. While selecting CTMS systems, it is essential for companies engaged in clinical research to ensure that these platforms are able to configure both, group and individual permissions, along with having a data backup and recovery plan for hosted systems. This will allow companies to assess the privacy and security implications of research and anticipate complications that may arise in each phase of the project. Assess the Scalability Choosing a scalable CTMS that can accommodate various types of fluctuations and expansions enables biotech and clinical firms to quickly adapt to fast-changing trends and demand spikes while reducing maintenance costs and enhancing user agility. As scalability also means secure and expanded data storage, these businesses should instead use SaaS solutions than manually manage an ever-growing collection of hard drives. The right CTMS ensures accommodating the firm’s availability requirements without incurring the capital costs associated with expanding a physical infrastructure. The Closing Thought A well-executed and successful clinical trial involves multiple stages and processes. Several quality controls and stringent adherence to regulations are essential for the steps, along with efficient cross-departmental processes and procedures. Incorporating the right CTMS paves the way for paperless data collection, regulatory filing, and fiscal management tools for biotech researchers and administrative personnel.

Read More
Research

Nanostructures: Emerging as Effective Carriers for Drug Delivery

Article | July 11, 2022

Natural remedies have been employed in medicine since antiquity. However, a large number of them fail to go past the clinical trial stages. In vivo instability, poor solubility and bioavailability, a lack of target-specific delivery, poor absorption, and side effects of the medication are only a few of the problems caused by the use of large-sized materials in drug administration. Therefore, adopting novel drug delivery systems with targeted medications may be a solution to address these pressing problems. Nanotechnology has received tremendous attention in recent years and has been demonstrated to help blur the boundaries between the biological and physical sciences. With great success, it plays a vital part in enhanced medication formulations, targeted venues, and controlled drug release and delivery. Limitations of Traditional Delivery Trigger the Adoption of Nanoparticles The field of nanotechnology and the creation of drug formulations based on nanoparticles is one that is expanding and showcasing great potential. It has been thoroughly researched in an effort to develop new methods of diagnosis and treatment and to overcome the limitations of several diseases' current therapies. As a result, nanoparticles are being used to improve the therapeutic effectiveness and boost patient adherence to treatment by increasing medication bioavailability, drug accumulation at a particular spot, and reducing drug adverse effects. The nanoparticles could be transformed into intelligent systems housing therapeutic and imaging agents by manipulating their surface properties, size, correct drug load, and release with targeted drug delivery. Nanostructures facilitate the release of combination medications at the prescribed dose since they remain in the blood circulation system for a long time. Therefore, they result in fewer plasma fluctuations with decreased side effects. Due to their nanoscale, these structures can easily enter the tissue system, promote the absorption of drugs by cells, make medication administration more effective, and ensure that the medicine acts at the targeted location. The Way Ahead Nanomedicine and nano-delivery systems are a comparatively new but fast-evolving science in which nanoscale materials are used as diagnostic tools to deliver drug molecules at precisely targeted sites in a controlled manner. It is finding applications for the treatment of diseases such as cardiovascular, neurodegenerative, cancer, ocular, AIDS, and diabetes, among others. With more research and technological advancement, these drug delivery solutions will open up huge opportunities for companies that work with them.

Read More
MedTech

Advancement in Genomics Accelerating its Penetration into Precision Health

Article | July 12, 2022

Genomics is an interdisciplinary field of biology emphasizing the structure, editing, evolution, function, and mapping of genomes. It is creating deeper inroads across the precision health domain with the increasing introduction of advanced technologies such as quantum simulation, next-generation sequencing (NGS), and precise genome manipulation. As precision health focuses on providing the proper intervention to the right patient at the right time, genomics increasingly finds applications in human and pathogen genome sequencing in clinical and research spaces. Rising Hereditary Diseases Burden Paving the Way for Genomics in Precision Health In the last few years, a significant surge in the prevalence of diseases and ailments such as diabetes, obesity, baldness, and others has been witnessed across the globe. A history of family members with chronic diseases, such as cancer, diabetes, high blood pressure, hearing issues, and heart disease, can sometimes continue into the next generation. Hence, the study of genes is extensively being conducted for predicting health risks and early treatment of these diseases. It also finds use in CRISPR-based diagnostics and the preparation of precision medication for the individual. In addition, ongoing advancements in genomics are making it possible to identify different genetic traits that persuade people to more widespread diseases and health problems. The Emergence of Genomics Improves Disease Understanding Genomics refers to the study of the complete genetic makeup of a cell or organism. Increasing scientific research in the area substantially contributes to increasing knowledge about the human genome and assists in improving the ability to understand disease etiology, risk, diagnosis, treatment, and prevention. On account of these improvements, innovative genomic technologies and tools are being developed to enable better precision health not only for the individual but for various regional populations as well. The Way Forward With growing preference for personalized medicine and an increasing need for more accurate pathogen detection and diagnostics, genomics is gaining huge popularity across the precision health domain. Also, increasing research activities for developing novel high-precision therapeutics and rising importance of gene study in the prevention, diagnosis, and management of infectious and genetic diseases will further pave the way for genomics in the forthcoming years.

Read More
MedTech

Next-Gen Genetics Cancer Therapies Creating Investment Prospects

Article | July 5, 2022

Genetic therapeutics such as genetic engineering and gene therapy are increasingly emerging as one of the most influential and transformed biotechnological solutions around the globe in recent times. These genetic solutions are being assessed across various medical domains, including cancer treatment, neurology, oncology, and ophthalmology. Citing the trend, the genetics industry is estimated to experience a tsunami of approvals, with over 1,000 cell and gene therapy clinical trials currently underway and over 900 companies worldwide focusing on these cutting-edge therapies. Growing Cancer Encourages Advancements in Genetic Technologies With the surging cases of cancers such as leukemias, carcinomas, lymphomas, and others, patients worldwide are increasing their spending on adopting novel therapeutic solutions for non-recurring treatment of the disease, such as gene therapy, genetic engineering, T-cell therapy, and gene editing. As per a study by the Fight Cancer Organization, spending on the treatment of cancer increased to $200.7 billion, and the amount is anticipated to exceed $245 billion by the end of 2030. Growing revenue prospects are encouraging biotechnology and biopharmaceutical companies to develop novel genetic solutions for cancer treatment. For instance, Bristol-Myers Squibb K.K., a Japanese pharmaceutical company, introduced a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, Abecma, for the treatment of relapsed or refractory (R/R) multiple myeloma in 2022. Amid a New Market: Genetics Will Attract Massive Investments Despite several developments and technological advancements, genetics is still considered to be in a nascent stage, providing significant prospects for growth to the companies that are already operating in the domain. Genetics solutions such as gene therapies, gene editing, and T-cell immunotherapy are emerging as highly active treatments across various medical fields, resulting in increasing research and development activities across the domain, drawing significant attention from investors. Given the potential of genetic treatments and the focus on finding new ways to treat cancer and other related diseases, it's easy to understand why companies are investing in the domain. For instance, Pfizer has recently announced an investment of around $800 million to construct development facilities supporting gene therapy manufacturing from initial preclinical research through final commercial-scale production. Due to these advancements, cell and gene therapies are forecast to grow from $4 billion annually to more than $45 billion, exhibiting growth at a 63% CAGR. The Future of Genetics Though there is a significant rise in advancement in genetic technologies and developments, the number of approved genetic treatments remains extremely small. However, with gene transfer and CRISPR solutions emerging as new modalities for cancer treatment, the start-up companies will attract a growing amount and proportion of private and public investments. This is expected present a tremendous opportunity for biopharma and biotechnology investors to help fund and benefit from the medical industry's shift from traditional treatments to cutting-edge genetic therapeutics in the coming years.

Read More

Spotlight

Aspetar

Aspetar is the first specialised Orthopaedic and Sports Medicine Hospital in the Gulf region. It provides the highest possible medical treatment for sports-related injuries in a state-of-the-art facility, staffed by some of the world’s leading sports medicine practitioners and researchers. Through the delivery of excellence in sports medicine, physiotherapy, sports science, orthopaedic surgery and rehabilitation, Aspetar services the needs of football and Sports Clubs and Federations throughout the state of Qatar, and regularly services international athletes and professional sportspeople.

Related News

RNA-protein network may explain why melanoma grows more

Phys.org | October 29, 2018

With five-year survival rates being around 30 percent for patients with distant metastatic disease, cutaneous melanoma is the leading cause of skin cancer-related deaths. The major causes of the low survival rate for melanoma patients are the limited number of options for patients lacking the BRAF mutation and the intrinsic and acquired resistance to existing therapies. It is therefore essential to develop new therapeutic strategies to eradicate resistant cells and/or target patients irrespective of their driver mutations. A collaboration led by scientists from KU Leuven, Belgium, with Tokyo University of Agriculture and Technology (TUAT), Japan, revealed a new way to fight melanoma. They report that a melanoma-specific long non-coding RNA, named SAMMSON, interacts with the protein CARF to properly coordinate protein synthesis in both the cytosol and mitochondria of melanoma cells. This mechanism ensures the maintenance of proteostasis during cell growth, thus avoiding the induction of cell death.

Read More

Study reveals best use of wildflowers to benefit crops on farms

Phys.org | October 16, 2018

With bee pollinators in decline and pesky crop pests lowering yields, sustainable and organic farmers need environmentally friendly solutions. One strategy is to border crops with wildflower plantings to attract pollinators and pest predators. But scientists have suggested that such plantings may only be effective when farms are surrounded by the right mix of natural habitat and agricultural land. For the first time, a Cornell University study of strawberry crops on New York farms tested this theory and found that wildflower strips on farms added pollinators when the farm lay within a "Goldilocks zone," where 25 to 55 percent of the surrounding area contained natural lands. Outside this zone, flower plantings also drew more strawberry pests, while having no effect on wasps that kill those pests.

Read More

The government is going to counter ‘misinformation’ about GMO foods

bioteh | May 03, 2017

The Food and Drug Administration will fund a campaign to promote genetically modified organisms in food under a bipartisan agreement to keep the government funded through the end of September.

Read More

RNA-protein network may explain why melanoma grows more

Phys.org | October 29, 2018

With five-year survival rates being around 30 percent for patients with distant metastatic disease, cutaneous melanoma is the leading cause of skin cancer-related deaths. The major causes of the low survival rate for melanoma patients are the limited number of options for patients lacking the BRAF mutation and the intrinsic and acquired resistance to existing therapies. It is therefore essential to develop new therapeutic strategies to eradicate resistant cells and/or target patients irrespective of their driver mutations. A collaboration led by scientists from KU Leuven, Belgium, with Tokyo University of Agriculture and Technology (TUAT), Japan, revealed a new way to fight melanoma. They report that a melanoma-specific long non-coding RNA, named SAMMSON, interacts with the protein CARF to properly coordinate protein synthesis in both the cytosol and mitochondria of melanoma cells. This mechanism ensures the maintenance of proteostasis during cell growth, thus avoiding the induction of cell death.

Read More

Study reveals best use of wildflowers to benefit crops on farms

Phys.org | October 16, 2018

With bee pollinators in decline and pesky crop pests lowering yields, sustainable and organic farmers need environmentally friendly solutions. One strategy is to border crops with wildflower plantings to attract pollinators and pest predators. But scientists have suggested that such plantings may only be effective when farms are surrounded by the right mix of natural habitat and agricultural land. For the first time, a Cornell University study of strawberry crops on New York farms tested this theory and found that wildflower strips on farms added pollinators when the farm lay within a "Goldilocks zone," where 25 to 55 percent of the surrounding area contained natural lands. Outside this zone, flower plantings also drew more strawberry pests, while having no effect on wasps that kill those pests.

Read More

The government is going to counter ‘misinformation’ about GMO foods

bioteh | May 03, 2017

The Food and Drug Administration will fund a campaign to promote genetically modified organisms in food under a bipartisan agreement to keep the government funded through the end of September.

Read More

Events